Investigational Compound Granted FDA Orphan Drug Designation
U.S. FDA Grants Orphan Drug Designation to Investigational Compound for Idiopathic Pulmonary Fibrosis
Search
Citizen Petition
Citizen Petition
Why cancer care is personal for us
At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.
BI Cares PAP portal
BI Cares PAP portal
Heart Failure
Heart Failure
Cancer
Cancer
Animal Health: Our Responsibility
BI's commitment to animal health is reflected in our more than 100 years of successful company history. It is also at the core of sustainability.
Mental Health
Mental Health
Dirk Stenkamp
Dirk Stenkamp, Senior Vice President Research Site Germany, reflects on our culture of collaboration and passion for progress.
Edda Dankmeyer
Edda Dankmeyer leads Sustainable Development Communications and explains how sustainable development can bea key differentiator for the company.
Galym Zhunisbekov
Galym Zhunisbekov, a Regional Regulatory Affairs Manager in Eastern Europe, talks about our philosophy and impact on patients’ lives.
Immunology
Immunology
Oncology & Cancer Immunology
Oncology & Cancer Immunology
Corporate Profile
Corporate Profile
Our people
Ambition. Passion. Integrity. Commitment. Empathy. Individuality. We expect these qualities at all levels.
Anna Race
Human Pharma Sales Director for UK & Ireland, Anna Race discusses how she enjoys making a difference within the company.
Lothar Halmer
Dr. Lothar Halmer is our Chief Quality Officer, and proud to have built a 25-year career with us.
Discovery Research Global Post-Doc Program
Discovery Research Global Post-Doc Program
Grass Roots
Grass Roots
Oncology Partnering Interests | Boehringer Ingelheim US
Click here to view our range of downloads on Boehringer Ingelheim's oncology & cancer immunology partnering interests.
Partnering-Boehringer-Ingelheim.pdf
BIPI Post Marketing Requirements PDF | Boehringer Ingelheim US
Our Retinal Health Partnering Interests
Our Retinal Health Partnering Interests
Partnering Interests in CardioMetabolic Diseases
Partnering Interests in CardioMetabolic Diseases
More Green | Sustainable Development | Boehringer Ingelheim US
Our MORE GREEN pillar encompasses initiatives that consider many different aspects: adopting measures to avoid water and air pollution, & much more.